RxDoctor Payments Data

Ricardo Lugo, MD

Clinical Cardiac Electrophysiology · Nashville, TNNPI 1437449253

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Philips North America LLC at 30.3% of the total.

$32,771in general payments, 2019–2025

Across 192 payments — averaging $170.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$10K
  • Biosense Webster, Inc.$7K
  • Medtronic$7K
  • Boston Scientific$4K
  • Abbott$3K
  • Biotronik Inc.$640
  • plus $612 from 10 others

What the payments were for

  • Consulting fees$17,20052%
  • Travel & lodging$8,15225%
  • Food & beverage$7,42023%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,771 in reported general payments places this provider in the 75th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

See all clinical cardiac electrophysiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$491,082
Medicare patients
1,076
Services billed
5,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban648$638,165
XareltoRivaroxaban113$134,854
FarxigaDapagliflozin Propanediol70$48,967
JardianceEmpagliflozin55$47,597
EntrestoSacubitril/Valsartan22$31,261
MultaqDronedarone Hcl12$20,791
Flecainide Acetate243$8,745
Metoprolol Succinate346$5,774
Mexiletine Hcl49$5,548
Amiodarone Hcl235$4,856
Dofetilide31$4,371
Diltiazem 24hr Er (Cd)Diltiazem Hcl80$2,365
Bisoprolol Fumarate74$2,014
Atorvastatin Calcium94$1,213
Acebutolol Hcl14$1,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$638,165648 claims
Johnson & JohnsonXarelto$48$134,854113 claims
AstraZenecaFarxiga$17$48,96770 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

Other clinical cardiac electrophysiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →